Serum neprilysin and recurrent hospitalizations after acute heart failure

International Journal of Cardiology

Volumn 220, Issue , 2016, Pages 742-744

  Núñez, Julio ^a   Núñez, Eduardo ^a   Miñana, Gema ^a   Carratalá, Arturo ^a   Sanchis, Juan ^a   Lupón, Josep ^b   Barallat, Jaume ^b   Pastor, Maria Cruz ^b   Pascual Figal, Domingo ^c   Bayés Genís, Antoni ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

Acute heart failure; Neprilysin; Rehospitalizations

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; ELISA KIT; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TWO DIMENSIONAL ECHOCARDIOGRAPHY; BLOOD; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; HEART FAILURE; HOSPITALIZATION; MIDDLE AGED; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; PATIENT READMISSION; PROSPECTIVE STUDIES;

EID: 84978160778     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.06.271     Document Type: Article

References (10)

1. [1] Braunwald, E., The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J. Am. Coll. Cardiol. 65 (2015), 1029–1041.
2. [2] Bayes-Genis, A., Barallat, J., Galan, A., de Antonio, M., Domingo, M., Zamora, E., et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J. Am. Coll. Cardiol. 65 (2015), 657–665.
3. [3] Bayes-Genis, A., Barallat, J., Galán, A., de Antonio, M., Domingo, M., Zamora, E., et al. Multimarker strategy for heart failure prognostication. Value of neurohormonal biomarkers: neprilysin vs NT-proBNP. Rev. Esp. Cardiol. 68 (2015), 1075–1084.
4. [4] Bayés-Genís, A., Barallat, J., Pascual, D., Nuñez, J., Miñana, G., Sánchez-Mas, J., et al. Prognostic value and kinetics of soluble neprilysin in acute heart failure: a pilot study. JACC Heart Fail. 3 (2015), 641–644.
5. [5] Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J.J., Ponikowski, P., Poole-Wilson, P.A., et al. ESC Committee for practice guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 29 (2008), 2388–2442.
6. [6] McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al. ESC Committee for practice guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur. Heart J. 33 (2012), 1787–1847.
7. [7] Rogers, J.K., Pocock, S.J., McMurray, J.J., Granger, C.B., Michelson, E.L., Östergren, J., et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-preserved. Eur. J. Heart Fail. 16 (2014), 33–40.
8. [8] McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al., PARADIGM-HF Investigators and Committees, Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371 (2014), 993–1004.
9. [9] Packer, M., McMurray, J.J., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al., PARADIGM-HF Investigators and Coordinators, Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
10. [10] Jhund, P.S., Fu, M., Bayram, E., Chen, C.H., Negrusz-Kawecka, M., Rosenthal, A., et al., PARADIGM-HF Investigators and Committees, Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur. Heart J. 36 (2015), 2576–2584.